Eric Bouffet et al. (20) demonstrated in a phase II clinical trial that for children with low-grade gliomas with BRAF V600 mutations, the combination of dabrafenib and trametinib as the first-line treatment resulted in more responses, longer progression-free survival, and better safety compared to standard chemotherapy. The gene discussed is BRAF; the disease is glioma.